To address the need for personalized oncology drug testing, CEO Ishani Malhotra founded Carcinotech, the Edinburgh-based biotech company that is bioprinting patient-specific testing models with cells from biopsy samples. Find out how these ingenious researchers benefited from expert support from CELLINK, a BICO company.
Carcinotech produces 3D bioprinted tumor models using patient-derived cancer stem cells, primary cells and established cell lines. They developed their testing platform to enable rapid, ethical, sustainable and personalized drug testing. Because patients have different genetic makeups, a drug that works for one person might not work for others. Some chemotherapy drugs, temozolomide for example, will only work for 50% of patients. It is important to conduct individualized drug testing to ensure that the other 50% with a certain genetic mutation are identified. Then we can prescribe other drugs in the pipeline that will help them fight the cancer.